← Heron Therapeutics, Inc. (HRTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Heron Therapeutics, Inc. (HRTX)
Pharmaceutical Preparations · market cap $55M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
13
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Heron Therapeutics (HRTX) is a small-cap specialty pharma with 122 employees and a ~$79M market cap trading at ~$0.42/share. The company generates meaningful revenue (~$155M in 2025) anchored by its postoperative pain and CINV franchise, but carries $82.2M in net debt against only $26.1M cash despite a reported ~51-month runway, raising questions about the underlying cash flow profile.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bupivacaine HCl | Phase 3 | Postoperative Pain |
| HTX-011A | Phase 2 | Postoperative Pain |
| APF530 | Phase 3 | Nausea and Vomiting |
| Bupivacaine HCl without epinephrine | Phase 2 | Postoperative Pain |
| Bupivicaine HCl | Phase 2 | Postoperative Pain |
| HTX-034 | Phase 2 | Bunions |
| Bupivacaine HCI (Marcaine) | Phase 2 | Postoperative Pain |
| aprepitant | Phase 2 | Postoperative Pain |
| Bupivacaine HCI without epinephrine | Phase 2 | Post-Operative Pain |
| HTX-011 | Phase 3 | Postoperative Pain |
| Ketorolac | Phase 2 | Postoperative Pain |
| HTX-011B | Phase 2 | Postoperative Pain |
| B10 L-BPA Injection | Phase 2 | Meningioma |
Price & technical context
3-month
-25.0%
6-month
-58.8%
12-month
-73.8%
52-wk range
$0.27–$1.49
vs 50-day MA
-7.9%
vs 200-day MA
-59.0%
Realized vol
97.8%
Max drawdown
-89.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.